Filing Flows › Selectis Health (GBCS) › Takeover & LBO
Is Selectis Health (GBCS) a takeover target?
A leveraged buyout does not work for Selectis Health on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-07-13): Response to a tender offer (Schedule 14D-9).
Why a leveraged buyout does not fit
The buyout model needs Selectis Health's revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers on record paid a median premium of 32.5% over the share price before the deal (the middle half 20% to 51.8%), according to the 1,437 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-07-13 · SC 14D9 · Response to a tender offer (Schedule 14D-9)
- 2026-03-25 · SC 14D9 · Response to a tender offer (Schedule 14D-9)
Selectis Health's latest quarter
Selectis Health, Q2 2026: revenue $4.7M (-55% year over year), operating margin -44.5%, net earnings $8.1M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Questions
Is Selectis Health being acquired?
The latest signal on file is from 2026-07-13: Response to a tender offer (Schedule 14D-9). A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Selectis Health?
A leveraged buyout does not work for Selectis Health on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.